Literature DB >> 11103915

Contextual fear conditioning and baseline startle responses in the rat fear-potentiated startle test: a comparison of benzodiazepine/gamma-aminobutyric acid-A receptor agonists.

M R Guscott1, G P Cook, L J Bristow.   

Abstract

In the rat, fear-potentiated startle (FPS) test animals are first trained to associate brief light presentations with a mild electric footshock and then tested for startle responses to acoustic stimuli, delivered either in darkness (i.e. baseline startle) or after the conditioning stimulus. Following light presentation the magnitude of the startle response is markedly increased, and the test is commonly used to distinguish anxiolytic drug effects (i.e. a reduction in FPS) from non-specific effects such as sedation/muscle relaxation. However, recent studies suggest that the environment in which the animal is trained may also contribute towards the acquisition of a conditioned fear response (i.e. contextual fear conditioning) and that this may elevate startle responses recorded in the dark. In the present study, therefore, we have compared the benzodiazepine/gamma-aminobutyric acid-A receptor agonist chlordiazepoxide with the partial agonists FG 8205 and bretazenil, which are known to have a reduced propensity to produce sedation/myorelaxation, using two different FPS procedures: (i) conditioning and testing in stabilimeter chambers, and (ii) conditioning and testing in different environments. The results show that FPS can be demonstrated in both procedures and that treatment with chlordiazepoxide, FG 8205 or bretazenil dose-dependently attenuates the response. However, animals conditioned and tested in stabilimeter chambers also showed a significant increase in dark-startle amplitudes compared with non-shocked rats, suggesting that this response was elevated by contextual fear conditioning. Furthermore, despite clear differences in side-effect liabilities, FG 8205 and bretazenil significantly reduced dark-startle responses, suggesting that this measure is also sensitive to the anxiolytic effects of benzodiazepines. In contrast, when animals were conditioned and tested in different environments, dark-startle responses were not significantly different from those recorded in non-shocked rats and treatment with FG 8205 or bretazenil had no effect. Thus, conditioning and testing animals in different environments may provide a more effective means of distinguishing anxiolytic from non-specific drug effects in the rat FPS test.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11103915     DOI: 10.1097/00008877-200009000-00006

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  12 in total

1.  Reduction of fear-potentiated startle by benzodiazepines in C57BL/6J mice.

Authors:  Kiersten S Smith; Edward G Meloni; Karyn M Myers; Ashlee Van't Veer; William A Carlezon; Uwe Rudolph
Journal:  Psychopharmacology (Berl)       Date:  2010-10-05       Impact factor: 4.530

2.  Drugs, sweat, and fears: a comparison of the effects of diazepam and methylphenidate on fear conditioning.

Authors:  Catherine M Brignell; H Valerie Curran
Journal:  Psychopharmacology (Berl)       Date:  2006-05-03       Impact factor: 4.530

3.  Superadditive effects of ethanol and flunitrazepam: implications of using immunopharmacotherapy as a therapeutic.

Authors:  Jennifer B Treweek; Amanda J Roberts; Kim D Janda
Journal:  Mol Pharm       Date:  2010-09-17       Impact factor: 4.939

4.  Sex differences in anxiety, sensorimotor gating and expression of the alpha4 subunit of the GABAA receptor in the amygdala after progesterone withdrawal.

Authors:  M Gulinello; R Orman; S S Smith
Journal:  Eur J Neurosci       Date:  2003-02       Impact factor: 3.386

5.  Phasic and sustained fear are pharmacologically dissociable in rats.

Authors:  Leigh Miles; Michael Davis; David Walker
Journal:  Neuropsychopharmacology       Date:  2011-04-06       Impact factor: 7.853

Review 6.  Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs anxiety.

Authors:  Michael Davis; David L Walker; Leigh Miles; Christian Grillon
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

7.  Relation between corticosterone and fear-related behavior in mice selectively bred for high or low alcohol preference.

Authors:  Julia A Chester; Aaron M Kirchhoff; Gustavo D Barrenha
Journal:  Addict Biol       Date:  2013-01-21       Impact factor: 4.280

8.  Comparison of the effects of the GABAB receptor positive modulator BHF177 and the GABAB receptor agonist baclofen on anxiety-like behavior, learning, and memory in mice.

Authors:  Xia Li; Victoria B Risbrough; Chelsea Cates-Gatto; Katarzyna Kaczanowska; M G Finn; Amanda J Roberts; Athina Markou
Journal:  Neuropharmacology       Date:  2013-01-29       Impact factor: 5.250

9.  Prevention of drug-induced memory impairment by immunopharmacotherapy.

Authors:  Jennifer B Treweek; Chengzao Sun; Alexander V Mayorov; Longwu Qi; Coree L Levy; Amanda J Roberts; Tobin J Dickerson; Kim D Janda
Journal:  J Med Chem       Date:  2008-10-16       Impact factor: 7.446

10.  Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbils.

Authors:  Scott A Heldt; Michael Davis; Emiliangelo Ratti; Mauro Corsi; David Trist; Kerry J Ressler
Journal:  Behav Pharmacol       Date:  2009-10       Impact factor: 2.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.